^
    Back
    Association details:
    Biomarker:CD9 expression
    Cancer:B Acute Lymphoblastic Leukemia
    Drug:KBA1412 (CD9 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ESMO 2020
    Title:

    582P - Preclinical development of AT1412, a patient derived CD9 antibody that does not induce thrombosis for treatment of precursor B ALL

    Published date:
    09/14/2020
    Excerpt:
    ...CD9 on B-ALL cells can be successfully targeted by AT1412. AT1412 targets a unique epitope and does not induce thrombosis. Pre-clinical safety assessment is supporting that AT1412 can be safely administered.